Posted originally on the conservative tree house on August 25, 2022 | Sundance
In April 2022, the Biden administration ordered 20 million doses of Pfizer’s antiviral Covid-19 treatment called Paxlovid.
Now a study published in the New England Journal of Medicine shows the medication shows “no measurable benefit” for the treatment of COVID-19 in patients 40 to 65-years of age.
WASHINGTON — Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
The results from a 109,000-patient Israeli study are likely to renew questions about the U.S. government’s use of Paxlovid, which has become the go-to treatment for COVID-19 due to its at-home convenience. The Biden administration has spent more than $10 billion purchasing the drug and making it available at thousands of pharmacies through its test-and-treat initiative.
The researchers found that Paxlovid reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection. That’s consistent with earlier results used to authorize the drug in the U.S. and other nations.
But people between the ages of 40 and 65 saw no measurable benefit, according to the analysis of medical records. (read more)